ISTA Pharmaceuticals Announces New Phase III Clinical Findings To Support Bepreve NDA Filing

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced positive results from the preliminary analysis of its second and final Bepreve(TM) (bepotastine ophthalmic solution) Phase III clinical study. The U.S. multi-center conjunctival allergen challenge (CAC) study evaluated the onset and duration of effect of two Bepreve concentrations in 130 patients with a history of ocular allergies. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: